Experimental plasmacytomagenesis in mice

Hematology/Oncology Clinics of North America

Volumn 11, Issue 2, 1997, Pages 323-347

  Potter, M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKANE; CD40 ANTIGEN; INDOMETACIN; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MICROTUBULE ASSOCIATED PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PARAFFIN; PLASTIC; PROSTAGLANDIN E2; REACTIVE OXYGEN METABOLITE; SILICON DERIVATIVE; SOMATOMEDIN RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL MODEL; B LYMPHOCYTE; CARCINOGENESIS; CELL DIFFERENTIATION; CHROMOSOME TRANSLOCATION; EXPERIMENTAL NEOPLASM; INFLAMMATION; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; ONCOGENE C MYC; OXIDATION; PERITONITIS; PLASMA CELL; PLASMACYTOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE;

EID: 0031001374     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(05)70434-2     Document Type: Article

References (136)

1. J.M. Adams A.W. Harris C.A. Pinkert The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice Nature 318 1985 533
2. E.D. Anastassiou F. Paliogianni J.P. Balow Prostaglandin E2 and other cyclic AMP-elevating agents modulate IL-2 and IL-2R alpha gene expression at multiple levels J Immunol 148 1992 2845
3. A.O. Anderson J.S. Wax M. Potter Differences in the peritoneal response to pristane in BALB/cAnPt and BALB/cJ mice Curr Top Microbiol Immunol 122 1985 242
4. P.N. Anderson Plasma cell tumor induction in BALB/c mice Proc Am Assoc Cancer Res 11 1970 3
5. P.N. Anderson M. Potter Induction of plasma cell tumours in BALB-c mice with 2, 6, 10, 14-tetramethylpentadecane (pristane) Nature 222 1969 994
6. T.J. Athanassiades R.S. Speirs Formation of antigen-induced granulomas containing plasma cells: A light and electron microscopic study Journal of the Reticuloendothelial Society 5 1968 485
7. T.J. Athanassiades R.S. Speirs Granuloma induction in the peritoneal cavity. A model for the study of inflammation and plasmacytopoiesis in nonlymphatic organs Journal of the Reticuloendothelial Society 11 1972 60
8. M. Auvinen A. Paasinen-Sohns H. Hirai Ornithine decarboxylase- and ras-induced cell transformations: Reversal by protein tyrosine kinase inhibitors and role of pp130CAS Mol Cell Biol 15 1995 6513
9. J. Banchereau F. Rousset Human B lymphocytes: Phenotype, proliferation, and differentiation Adv Immunol 52 1992 125
10. A. Barberis K. Widenhorn L. Vitelli A novel B-cell lineage-specific transcription factor present at early but not late stages of differentiation Genes Dev 4 1990 849
11. R. Baserga The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 55 1995 249
12. T.W. Behrens J.S. Goodwin Control of humoral immune responses by arachidonic acid metabolites Agents Actions 26 1989 15
13. C. Bello-Fernandez G. Packham J.L. Cleveland The ornithine decarboxylase gene is a transcriptional target of c-myc Proc Natl Acad Sci USA 90 1993 7804
14. D.J. Berg R.G. Lynch Immune dysfunction in mice with plasmacytomas. I. Evidence that transforming growth factor-beta contributes to the altered expression of activation receptors on host B lymphocytes J Immunol 146 1991 2865
15. E.M. Blackwood R.N. Eisenman Max: A helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc Science 251 1991 1211
16. M. Cancro M. Potter The requirement of an adherent cell substratum for the growth of developing plasmacytoma cells in vivo J Exp Med 144 1976 1554
17. R. Clynes J. Wax L.W. Stanton Rapid induction of IgM-secreting murine plasmacytomas by pristane and an immunoglobulin heavy-chain promoter/enhancer-driven c-myc/v-Ha-ras retrovirus Proc Natl Acad Sci USA 85 1988 6067
18. S. Cory Activation of cellular oncogenes in hemopoietic cells by chromosome translocation Adv Cancer Res 47 1986 189
19. S. Cory M. Graham E. Webb Variant (6;15) translocations in murine plasmacytomas involve a chromosome 15 locus at least 72 kb from the c-myc oncogene EMBO J 4 1985 675
20. J.W. Croese Experimental Approaches to the Treatment of Multiple Myeloma: Studies in an Animal Model 1987 Drukkerig Pasmaus B.O.'s Gravenhage Leiden
21. M. DeBenedette J.W. Olson E.C. Snow Expression of polyamine transporter activity during B lymphocyte cell cycle progression J Immunol 150 1993 4218
22. T.B. Dunn Plasma cell neoplasms beginning in the ileocecal area in strain C3H mice J Natl Cancer Inst 19 1957 371
23. K. Dux R.V. Rouse B. Kyewski Composition of the lymphoid cell populations from omental milky spots during the immune response in C57BL/Ka mice Eur J Immunol 16 1986 1029
24. M. Eilers S. Schirm J.M. Bishop The MYC protein activates transcription of the alpha-prothymosin gene EMBO J 10 1991 133
25. G.I. Evan A.H. Wyllie C.S. Gilbert Induction of apoptosis in fibroblasts by c-myc protein Cell 69 1992 119
26. W.M. Franz P. Berger J.Y.J. Wang Deletion of an N-terminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential EMBO J 8 1989 137
27. G.G. Freund D.T. Kulas R.A. Mooney Insulin and IGF-1 increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226 J Immunol 151 1993 1811
28. G.G. Freund D.T. Kulas B.A. Way Functional insulin and insulin-like growth factor-1 receptors are preferentially expressed in multiple myeloma cell lines as compared to B-lymphoblastoid cell lines Cancer Res 54 1994 3179
29. K. Galaktionov X. Chen D. Beach CDC25 cell-cycle phosphatase as a target of c-myc Nature 382 1996 511
30. K. Galaktionov A.K. Lee J. Eckstein CDC25 phosphatases as potential human oncogenes Science 269 1995 1575
31. E.R. Gauthier L. Piche G. Lemieux Role of bcl-X(L) in the control of apoptosis in murine myeloma cells Cancer Res 56 1996 1451
32. A.A. Geldof P. Rijnhart M.V.D. Ende Morphology, kinetics and secretory activity of antibody-forming cells Immunobiology 166 1984 296
33. P. Georgii-Hemming H.J. Wiklund O. Ljunggren Insulin-like growth factor I is a growth and survival factor in human multiple myeloma cell lines Blood 88 1996 2250
34. J.S. Goodwin J. Ceuppens Regulation of the immune response by prostaglandins J Clin Immunol 3 1983 295
35. P.R. Greipp N.M. Raymond R.A. Kyle Multiple myeloma: Significance of plasmablastic subtype in morphological classification Blood 65 1985 305
36. D.A. Grillot R. Merino J.C. Pena bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice J Exp Med 183 1996 381
37. J.C. Hengst M.B. Mokyr S. Dray Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors Cancer Res 41 1981 2163
38. M. Hibi K. Nakajima T. Hirano IL-6 cytokine family and signal transduction: A model of the cytokine system J Mol Med 74 1996 1
39. C.M. Hilkens A. Snijders H. Vermeulen Accessory cell–derived IL-12 and prostaglandin E2 determine the IFN-gamma level of activated human CD4+ T cells J Immunol 156 1996 1722
40. C.M. Hilkens H. Vermeulen van Neerven R.J. Differential modulation of T helper type 1 (Th1) and T helper type 2 (Th2) cytokine secretion by prostaglandin E2 critically depends on interleukin-2 Eur J Immunol 25 1995 59
41. R.M. Hinson J.A. Williams E. Shacter Elevated interleukin 6 is induced by prostaglandin E2 in a murine model of inflammation: Possible role of cyclooxygenase-2 Proc Natl Acad Sci USA 93 1996 4885
42. F. Ho J.E. Lortan I.C.M. MacLennan Distinct short-lived and long-lived antibody-producing cell populations Eur J Immunol 16 1986 1297
43. M. Holub I. Hajdu I. Trebichavsky Formation of lymphoid cells from local precursors in irradiated mouse omenta Eur J Immunol 1 1971 465
44. J. Jacob R. Kassir G. Kelsoe In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations J Exp Med 173 1991 1165
45. S. Janz J. Muller J. Shaughnessy Detection of recombinations between c-myc and immunoglobulin switch alpha in murine plasma cell tumors and preneoplastic lesions by polymerase chain reaction Proc Natl Acad Sci USA 90 1993 7361
46. D.F. Jelinek P.E. Lipsky The role of B cell proliferation in the generation of immunoglobulin-secreting cells in man J Immunol 130 1983 2597
47. D.F. Jelinek P.A. Thompson P.E. Lipsky Regulation of human B cell activation by prostaglandin E2 J Clin Invest 75 1985 1339
48. M. Kaleko W.J. Rutter A.D. Miller Overexpression of the human insulinlike growth factor I receptor promotes ligand-dependent neoplastic transformation Mol Cell Biol 10 1990 464
49. K. Katamura N. Shintaku Y. Yamauchi Prostaglandin E2 at priming of naive CD4+ T cells inhibits acquisition of ability to produce IFN-gamma and IL-2, but not IL-4 and IL-5 J Immunol 155 1995 4604
50. G.J. Kato C.V. Dang Function of the c-Myc oncoprotein FASEB J 6 1992 3065
51. T. Kishimoto S. Akira M. Narazaki Interleukin-6 family of cytokines and gp130 Blood 86 1995 1243
52. T. Kishimoto T. Taga S. Akira Cytokine signal transduction Cell 76 1994 253
53. B. Klein Cytokines, cytokine receptors, transduction signals, and oncogenes in human multiple myeloma Semin Hematol 32 1995 4
54. P.J. Knudsen C.A. Dinarello T.B. Strom Prostaglandins posttranscriptionally inhibit monocyte expression of interleukin 1 activity by increasing intracellular cyclic adenosine monophosphate J Immunol 137 1986 3189
55. R.J. Kulmacz W.E.M. Lands Stoichiometry and kinetics of the interaction of prostaglandin H synthase with anti-inflammatory agents J Biol Chem 260 1985 12572
56. D.A. Largaespada D.A. Kaehler H. Mischak A retrovirus that expresses v-abl and c-myc oncogenes rapidly induces plasmacytomas Oncogene 7 1992 811
57. P. Liu T. Leong L. Quam Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: Analysis of the Eastern Cooperative Oncology Group Phase III trial Blood 88 1996 2699
58. Y. Liu G.D. Johnson J. Gordon Germinal centres in T-cell–dependent antibody responses Immunol Today 13 1992 17
59. P.R. Lydyard J. Brostoff B.N. Hudspith Prostaglandin E2–mediated enhancement of human plasma cell differentiation Immunol Lett 4 1982 113
60. I.C. MacLennan D. Gray Antigen-driven selection of virgin and memory B cells Immunol Rev 91 1986 61
61. L. Madisen M. Groudine Identification of a locus control region in the immunoglobulin heavy-chain locus that deregulates c-myc expression in plasmacytoma and Burkitt's lymphoma cells Genes Dev 8 1994 2212
62. M.S. Mahmoud N. Huang M. Nobuyoshi Altered expression of Pax-5 gene in human myeloma cells Blood 87 1996 4311
63. S.D. Markowitz A.B. Roberts Tumor suppressor activity of the TGF-beta pathway in human cancers Cytokine Growth Factor Rev 7 1996 93
64. J.L. Masferrer B.S. Zweifel P.T. Manning Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic Proc Natl Acad Sci USA 91 1994 3228
65. C.A. Mattioli T.B.J. Tomasi The life span of IgA plasma cells from the mouse intestine J Exp Med 138 1973 452
66. B.J. Mayer D. Baltimore Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase Mol Cell Biol 14 1994 2883
67. R. Minakuchi M.C. Wacholtz L.S. Davis Delineation of the mechanism of inhibition of human T cell activation by PGE2 J Immunol 145 1990 2616
68. M.B. Mokyr S. Dray Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide Cancer Res 43 1983 3112
69. M.B. Mokyr A. Prokhorova M. Rubin Insight into the mechanism of TCR-V beta 8+/CD8+ T cell–mediated MOPC-315 tumor eradication J Immunol 153 1994 3123
70. M.B. Mokyr M. Rubin K.A. Newell Involvement of TCR-V beta 8.3+ cells in the cure of mice bearing a large MOPC-315 tumor by low dose melphalan J Immunol 151 1993 4838
71. Morse H.C. III J.W. Hartley M. Potter Genetic considerations in plasmacytomas of BALB/c NZB and (BALB/c × NZB)F1 mice Potter M. Progress in Myeloma. Biology of Myeloma 1980 Elsevier New York 263
72. J.R. Muller G.M. Jones S. Janz Migration of cells with immunoglobulin/c-myc recombinations in lymphoid tissues of mice Blood 1997 89
73. J.R. Muller M. Potter S. Janz Differences in the molecular structure of c-myc–activating recombinations in murine plasmacytomas and precursor cells Proc Natl Acad Sci USA 91 1994 12066
74. J.F. Mushinski c-myc oncogene activation and chromosomal translocation in BALB/c plasmacytomas Klein G. Cellular Oncogene Activation 1988 Marcel Dekker New York 181 222
75. M. Negishi T. Nambat Y. Sugimoto Opposite coupling of prostaglandin E receptor EP3C with Gs and Go J Biol Chem 268 1993 26067
76. M.F. Neurath W. Strober Y. Wakatsuki The murine lg 3′ alpha enhancer is a target site with repressor function for the B cell lineage–specific transcription factor BSAP (NF-HB, S alpha-BP) J Immunol 153 1994 730
77. M.F. Neurath E.R. Stuber W. Strober BSAP: A key regulator of B-cell development and differentiation Immunol Today 16 1995 564
78. R.P. Nordan M. Potter A macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro Science 233 1986 566
79. T.J. Novak E.V. Rothenberg cAMP inhibits induction of interleukin 2 but not of interleukin 4 in T cells Proc Natl Acad Sci USA 87 1990 9353
80. S. Ohno S. Migita F. Wiener Chromosomal translocations activating myc sequences and transduction of v-abl are critical events in the rapid induction of plasmacytomas by pristane and Abelson virus J Exp Med 159 1984 1762
81. P.J. Owen-Lynch A.K. Wong A.D. Whetton v-Abl-mediated apoptotic suppression is associated with SHC phosphorylation without concomitant mitogen-activated protein kinase activation J Biol Chem 270 1995 5956
82. G. Packham J.L. Cleveland c-Myc and apoptosis Biochim Biophys Acta 1242 1995 11
83. H.G. Pauels C. Specht C. Becker Suppression of tumour-specific cytotoxic T-cell responses against the syngeneic BALB/c plasmacytoma ADJ-PC-5 by tumour-induced CD8+ regulatory T cells via IFN-gamma Scand J Immunol 43 1996 421
84. F.E.M. Paulin M.J. West N.F. Sullivan Aberrant translational control of the c-myc gene in multiple myeloma Oncogene 13 1996 505
85. W.S. Pear G. Wahlstrom S.F. Nelson 6;7 chromosomal translocation in spontaneously arising rat immunocytomas: Evidence for c-myc breakpoint clustering and correlation between isotypic expression and the c-myc target Mol Cell Biol 8 1988 441
86. C. Pellat-Deceunynck R. Bataille N. Robillard Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells Blood 84 1994 2597
87. M. Pettersson H. Jernberg-Wiklund Larsson L.-G. Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells Blood 79 1992 495
88. R.P. Phipps D. Lee V. Schad E-series prostaglandins are potent growth inhibitors for some B lymphomas Eur J Immunol 19 1989 996
89. R.P. Phipps S.H. Stein R.L. Roper A new view of prostaglandin E regulation of the immune response Immunol Today 12 1991 349
90. H.I. Pilgrim The relationship of chronic ulceration of the ileocecal junction to the development of reticuloendothelial tumors in mice Cancer Res 25 1965 53
91. J.P. Portanova Y. Zhang G.D. Anderson Selective neutralization of prostaglandin E2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo J Exp Med 184 1996 883
92. M. Potter Immunoglobulin-producing tumors and myeloma proteins in mice Physiol Rev 52 1972 631
93. M. Potter R.C. MacCardle Histology of developing plasma cell neoplasia induced by mineral oil in BALB/c mice J Natl Cancer Inst 33 1964 497
94. M. Potter J.S. Wax Peritoneal plasmacytomagenesis in mice: Comparison of different pristane dose regimens J Natl Cancer Inst 71 1983 391
95. M. Potter F. Wiener Plasmacytomagenesis in mice: Model of neoplastic development dependent upon chromosomal translocations Carcinogenesis 13 1992 1681 1697
96. M. Potter S. Morrison F. Wiener Induction of plasmacytomas with silicone gel in genetically susceptible strains of mice J Natl Cancer Inst 86 1994 1058
97. M. Potter E.B. Mushinski J.S. Wax Identification of two genes on chromosome 4 that determine resistance to plasmacytoma induction in mice Cancer Res 54 1994 1
98. M. Potter J.S. Wax A.O. Anderson Inhibition of plasmacytoma development in BALB/c mice by indomethacin J Exp Med 161 1985 996
99. J. Radl J.W. Croese C. Zurcher Animal model of human disease. Multiple myeloma Am J Pathol 132 1988 593
100. G.D. Raffel K. Parmar N. Rosenberg In vivo association of v-Abl with Shc mediated by a non-phosphotyrosine-dependent SH2 interaction J Biol Chem 271 1996 4640
101. J.W. Rohrer K. Vasa R.G. Lynch Myeloma cell immunoglobulin expression during in vivo growth in diffusion chambers: Evidence for repetitive cycles of differentiation J Immunol 119 1977 861
102. M. Rollinghoff B.T. Rouse N.L. Warner Tumor immunity to murine plasma cell tumors. I. Tumor-associated transplantation antigens of NZB and BALB-c plasma cell tumors J Natl Cancer Inst 50 1973 159
103. R.L. Roper J.W. Ludlow R.P. Phipps Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins Cell Immunol 154 1994 296
104. H. Rosenbaum A.W. Harris M.L. Bath An E-mu-v-abl transgene elicits plasmacytomas in concert with an activated myc gene EMBO J 9 1990 897
105. G. Sainte-Marie Study on plasmocytopoieses. I. Description of plasmocytes and of their mitoses in the mediastinal lymph nodes of ten-week-old rats American Journal of Anatomy 114 1964 207
106. G. Sainte-Marie Cytokinetics of antibody-formation J Cell Physiol 67 1966 109
107. E. Shacter G.K. Arzadon J. Williams Elevation of interleukin-6 in response to a chronic inflammatory stimulus in mice: Inhibition by indomethacin Blood 80 1992 194
108. E. Shacter G.K. Arzadon J.A. Williams Stimulation of interleukin-6 and prostaglandin E2 secretion from peritoneal macrophages by polymers of albumin Blood 82 1993 2853
109. E. Shacter E.J. Beecham J.M. Covey Activated neutrophils induce prolonged DNA damage in neighboring cells Carcinogenesis 9 1988 2297
110. G.L. Shen-Ong E.J. Keath S.P. Piccoli Novel myc oncogene RNA from abortive immunoglobulin-gene recombination in mouse plasmacytomas Cell 31 1982 443
111. M. Shichiri K.D. Hanson J.M. Sedivy Effects of c-myc expression on proliferation, quiescence, and the G0 to G1 transition in nontransformed cells Cell Growth Differ 4 1993 93
112. S. Sirisinha H.N. Eisen Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins Proc Natl Acad Sci USA 68 1971 3130
113. D.S. Snyder D.I. Beller E.R. Unanue Prostaglandins modulate macrophage Ia expression Nature 299 1982 163
114. N. Stanford G.J. Roth T.Y. Shen Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin Prostaglandins 13 1977 669
115. P.S. Steeg H.M. Johnson J.J. Oppenheim Regulation of murine macrophage Ia antigen expression by an immune interferon-like lymphokine: Inhibitory effect of endotoxin J Immunol 129 1982 2402
116. P. Steiner A. Philipp J. Lukas Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes EMBO J 14 1995 4814
117. A. Strasser A.W. Harris S. Cory E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells Oncogene 8 1993 1
118. S. Suematsu T. Matsusaka T. Matsuda Generation of plasmacytomas with the chromosomal translocation t(12;15) in interleukin 6 transgenic mice Proc Natl Acad Sci USA 89 1992 232
119. T. Taga M. Hibi Y. Hirata Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp 130 Cell 58 1989 573
120. L.W.M.M. Terstappen S. Johnsen I.M.J. Segers-Nolten Identification and characterization of plasma cells in normal human bone marrow by high resolution flow cytometry Blood 76 1990 1739
121. C.B. Thompson P.B. Challoner P.E. Neiman Levels of c-myc oncogene mRNA are invariant throughout the cell cycle Nature 314 1985 363
122. J. Troppmair M. Potter J.S. Wax An altered v-raf is required in addition to v-myc in J3V1 virus for acceleration of murine plasmacytomagenesis Proc Natl Acad Sci USA 86 1989 9941
123. Turner C.A. Jr D.H. Mack M.M. Davis Blimp-1, a novel zinc finger-containing protein that can drive the maturation of B lymphocytes into immunoglobulinl-secreting cells Cell 77 1994 297
124. F.M. Uckun Regulation of human B-cell ontogeny Blood 76 1990 1908
125. M. Urashima A. Ogata D. Chauhan Transforming growth factor-beta1: Differential effects on multiple myeloma versus normal B cells Blood 87 1996 1928
126. M. Urashima A. Ogata D. Chauhan Interleukin-6 promotes multiple myeloma cell growth via phosphorylation of retinoblastoma protein Blood 88 1996 2219
127. van der Pouw Kraan T.C. L.C. Boeije R.J. Smeenk Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production J Exp Med 181 1995 775
128. A. Vink P. Coulie G. Warnier Mouse plasmacytoma growth in vivo: Enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor J Exp Med 172 1990 997
129. D.F. Weinberg E. Baldo-Correa H.L. Lenzi Schistosoma mansoni: Peritoneal plasmacytogenesis and polypoid transformation of mesenteric milky spots in infected mice Exp Parasitol 74 1992 408
130. L.M. Weiskirch Y. Bar-Dagan M.B. Mokyr Transforming growth factor-beta–mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor-bearing mice engaged in tumor eradication following low-dose melphalan therapy Cancer Immunol Immunother 38 1994 215
131. E.M. Weissinger H. Mischak D.A. Largaespada Induction of plasmacytomas secreting antigen-specific monoclonal antibodies with a retrovirus expressing v-abl and c-myc Proc Natl Acad Sci USA 88 1991 8735
132. M.E. Whisson T.A. Connors Cure of mice bearing advanced plasma cell tumors with aniline mustard Nature 206 1965 689
133. M.E. Whisson T.A. Connors Drug induced regression of large plasma cell tumours Nature 205 1965 406
134. M.F. White The IRS-1 signaling system Curr Opin Genet Dev 4 1994 47
135. M.F. White C.R. Kahn The insulin signaling system J Biol Chem 269 1994 1
136. N.M. Yeilding M.T. Rehman W.M.F. Lee Identification of sequences in c-myc mRNA that regulate its steady-state levels Mol Cell Biol 16 1996 3511